US 2013/0296401 A1 · HBV TREATMENT

Abstract

RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

Claims20

Dependent claims

A DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in one or more Hepatitis B virus (HBV) genes, the ddRNAi agent comprising:

a first effector sequence of at least 17 nucleotides in length;
a second effector sequence of at least 17 nucleotides in length
a second effector complement sequence;
and
a first effector complement sequence,
wherein each effector sequence is substantially complementary to the predicted transcript of a target sequence.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/882,124Filed 27 Oct 2011

Priority

CN 201010521948.328 Oct 2010

Published

7 Nov 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

C12N 15/1131
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against viruses
A61P 31/20
Antivirals: for DNA viruses
C12N 2310/14
Type of nucleic acid: interfering nucleic acids [NA]
C12N 2310/531
Partially self-complementary or closed: stem-loop; Hairpin

Hbv treatment

Life of this patent

Hbv treatment

Life of this patent

Abstract

Claims20